Ending the REMS cut the paperwork, but reimbursement that ignores clozapine’s added care demands still keeps the drug from patients who could benefit.
Jose M. Rubio, MD, PhD
Advertisement
Dr Rubio is an assistant professor of psychiatry at The Feinstein Institutes for Medical Research. He also leads research operations from the Division of Psychiatry Research at Zucker Hillside Hospital, in coordination with clinical and neuroimaging services at Northwell.
Articles by Jose M. Rubio, MD, PhD
Clinicians should keep in mind the risk-to-benefit ratio considerations before initiating polypharmacy, especially if they have patients with prescriptions inherited from several sources. Here: A summary of recommendations about the use of polypharmacy in psychotic disorders.
Which treatments have proven to be efficacious in meta-analyses as augmentation of clozapine in reducing positive symptoms of schizophrenia? The answer might surprise you.
Antipsychotic drugs are the cornerstone in the management of psychotic disorders, but most patients fail to have a “good” response in short-term trials. Alternative strategies are presented here.
Advertisement
Latest Updated Articles
Understanding the Risks and Benefits of Antipsychotic PolypharmacyFebruary 28th 2019
Mini Quiz: Antipsychotic PolypharmacyOctober 15th 2019
Advertisement
Advertisement
Trending on Psychiatric Times
1
FDA Grants Clearance to Motivista, the First Authorized Treatment for Negative Symptoms of Schizophrenia
2
Muscarinic Treatment for Schizophrenia: A Presynaptic Answer to a Presynaptic Problem
3
How a Learning Health Network Could Transform Bipolar Disorder Treatment: A Conversation With Andrew Nierenberg, MD
4
Blood-Based Biomarkers for Alzheimer Disease: Accuracy, Limits, and Confounders
5